New P32/gC1qR Ligands for Targeted Tumor Drug Delivery

Overview

Journal Chembiochem

Specialty Biochemistry

Date 2016 Feb 20

PMID 26895508

Citations 43

Authors

Lauri Paasonen

Shweta Sharma

Gary B Braun

Venkata Ramana Kotamraju

Thomas D Y Chung

Zhi-Gang She

Kazuki N Sugahara

Marjo Yliperttula

Bainan Wu

Maurizio Pellecchia

Erkki Ruoslahti

Tambet Teesalu

Affiliations

Soon will be listed here.

Abstract

Cell surface p32, the target of LyP-1 homing peptide, is upregulated in tumors and atherosclerotic plaques and has been widely used as a receptor for systemic delivery of payloads. Here, we identified an improved LyP-1-mimicking peptide (TT1, CKRGARSTC). We used this peptide in a fluorescence polarization-based high-throughput screening of a 50,000-compound chemical library and identified a panel of compounds that bind p32 with low micromolar affinity. Among the hits identified in the screen, two compounds were shown to specifically bind to p32 in multiple assays. One of these compounds was chosen for an in vivo study. Nanoparticles surface-functionalized with this compound specifically adhered to surfaces coated with recombinant p32 and, when injected intravenously, homed to p32-expressing breast tumors in mice. This compound provides a lead for the development of p32-targeted affinity ligands that circumvent some of the limitations of peptide-based probes in guided drug delivery.

Citing Articles

Effects of LinTT1-peptide conjugation on the properties of poly(ethylene glycol)-block-(ε-caprolactone) nanoparticles prepared by the nanoprecipitation method.

Kankanen V, Hirvonen S, Teesalu T, Hirvonen J, Balasubramanian V, Santos H Drug Deliv Transl Res. 2025; .

PMID: 39753999 DOI: 10.1007/s13346-024-01768-7.

Targeting vascular disrupting agent-treated tumor microenvironment with tissue-penetrating nanotherapy.

Sidorenko V, Scodeller P, Uustare A, Ogibalov I, Tasa A, Tshubrik O Sci Rep. 2024; 14(1):17513.

PMID: 39080306 PMC: 11289491. DOI: 10.1038/s41598-024-64610-7.

Protease-activated CendR peptides targeting tenascin-C: mitigating off-target tissue accumulation.

Tobi A, Haugas M, Rabi K, Sethi J, Posnograjeva K, Paiste P Drug Deliv Transl Res. 2024; 14(10):2945-2961.

PMID: 39012578 PMC: 11384632. DOI: 10.1007/s13346-024-01670-2.

Peptide-Hitchhiking for the Development of Nanosystems in Glioblastoma.

Branco F, Cunha J, Mendes M, Vitorino C, Sousa J ACS Nano. 2024; 18(26):16359-16394.

PMID: 38861272 PMC: 11223498. DOI: 10.1021/acsnano.4c01790.

Brain-targeted drug delivery - nanovesicles directed to specific brain cells by brain-targeting ligands.

Moreira R, Nobrega C, de Almeida L, Mendonca L J Nanobiotechnology. 2024; 22(1):260.

PMID: 38760847 PMC: 11100082. DOI: 10.1186/s12951-024-02511-7.

References

Owicki J . Fluorescence polarization and anisotropy in high throughput screening: perspectives and primer. J Biomol Screen. 2000; 5(5):297-306. DOI: 10.1177/108705710000500501. View

Agemy L, Kotamraju V, Friedmann-Morvinski D, Sharma S, Sugahara K, Ruoslahti E . Proapoptotic peptide-mediated cancer therapy targeted to cell surface p32. Mol Ther. 2013; 21(12):2195-204. PMC: 3863797. DOI: 10.1038/mt.2013.191. View

Zanuy D, Flores-Ortega A, Jimenez A, Calaza M, Cativiela C, Nussinov R . In silico molecular engineering for a targeted replacement in a tumor-homing peptide. J Phys Chem B. 2009; 113(22):7879-89. PMC: 2734192. DOI: 10.1021/jp9006119. View

Zanuy D, Sayago F, Revilla-Lopez G, Ballano G, Agemy L, Kotamraju V . Engineering strategy to improve peptide analogs: from structure-based computational design to tumor homing. J Comput Aided Mol Des. 2012; 27(1):31-43. PMC: 7553648. DOI: 10.1007/s10822-012-9623-5. View

Baell J, Walters M . Chemistry: Chemical con artists foil drug discovery. Nature. 2014; 513(7519):481-3. DOI: 10.1038/513481a. View

Braun G, Friman T, Pang H, Pallaoro A, Hurtado de Mendoza T, Willmore A . Etchable plasmonic nanoparticle probes to image and quantify cellular internalization. Nat Mater. 2014; 13(9):904-11. PMC: 4141013. DOI: 10.1038/nmat3982. View

Jha B, Salunke D, Datta K . Disulfide bond formation through Cys186 facilitates functionally relevant dimerization of trimeric hyaluronan-binding protein 1 (HABP1)/p32/gC1qR. Eur J Biochem. 2002; 269(1):298-306. DOI: 10.1046/j.0014-2956.2001.02654.x. View

Teesalu T, Sugahara K, Kotamraju V, Ruoslahti E . C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad Sci U S A. 2009; 106(38):16157-62. PMC: 2752543. DOI: 10.1073/pnas.0908201106. View

Zhang , Chung , OLDENBURG . A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen. 2000; 4(2):67-73. DOI: 10.1177/108705719900400206. View

10.

Luo G, Yu X, Jin C, Yang F, Fu D, Long J . LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors. Int J Pharm. 2009; 385(1-2):150-6. DOI: 10.1016/j.ijpharm.2009.10.014. View

11.

Barile E, Pellecchia M . NMR-based approaches for the identification and optimization of inhibitors of protein-protein interactions. Chem Rev. 2014; 114(9):4749-63. PMC: 4027952. DOI: 10.1021/cr500043b. View

12.

Laakkonen P, Porkka K, Hoffman J, Ruoslahti E . A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat Med. 2002; 8(7):751-5. DOI: 10.1038/nm720. View

13.

Park J, von Maltzahn G, Xu M, Fogal V, Kotamraju V, Ruoslahti E . Cooperative nanomaterial system to sensitize, target, and treat tumors. Proc Natl Acad Sci U S A. 2010; 107(3):981-6. PMC: 2824295. DOI: 10.1073/pnas.0909565107. View

14.

Park J, von Maltzahn G, Zhang L, Derfus A, Simberg D, Harris T . Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting. Small. 2009; 5(6):694-700. PMC: 3058937. DOI: 10.1002/smll.200801789. View

15.

Fujimori K, Covell D, Fletcher J, Weinstein J . A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med. 1990; 31(7):1191-8. View

16.

Yan Z, Wang F, Wen Z, Zhan C, Feng L, Liu Y . LyP-1-conjugated PEGylated liposomes: a carrier system for targeted therapy of lymphatic metastatic tumor. J Control Release. 2011; 157(1):118-25. DOI: 10.1016/j.jconrel.2011.07.034. View

17.

Hamzah J, Kotamraju V, Seo J, Agemy L, Fogal V, Mahakian L . Specific penetration and accumulation of a homing peptide within atherosclerotic plaques of apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A. 2011; 108(17):7154-9. PMC: 3084060. DOI: 10.1073/pnas.1104540108. View

18.

Chatterjee J, Rechenmacher F, Kessler H . N-methylation of peptides and proteins: an important element for modulating biological functions. Angew Chem Int Ed Engl. 2012; 52(1):254-69. DOI: 10.1002/anie.201205674. View

19.

Thomas V, Bhattachar S, Hitchingham L, Zocharski P, Naath M, Surendran N . The road map to oral bioavailability: an industrial perspective. Expert Opin Drug Metab Toxicol. 2006; 2(4):591-608. DOI: 10.1517/17425255.2.4.591. View

20.

Laakkonen P, Akerman M, Biliran H, Yang M, Ferrer F, Karpanen T . Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc Natl Acad Sci U S A. 2004; 101(25):9381-6. PMC: 438985. DOI: 10.1073/pnas.0403317101. View